Your session is about to expire
← Back to Search
Lebrikizumab Pen for Atopic Dermatitis
Phase 3
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1
Awards & highlights
Summary
The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose. Participants will complete the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ) following the simulated injection. This study involves one study visit.
Eligible Conditions
- Atopic Dermatitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants Who Responded Agree or Strongly Agree to the Confidence of Use Question Using the mSQAAQ
Number of Participants Who Responded Agree or Strongly Agree to the Ease of Use Question Using the Modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Lebrikizumab PenExperimental Treatment1 Intervention
Injection of lebrikizumab pen into a practice pad.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lebrikizumab Pen
2024
Completed Phase 3
~60
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,640 Previous Clinical Trials
3,221,589 Total Patients Enrolled
Study DirectorEli Lilly and Company
4 Previous Clinical Trials
1,092 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger